Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.
Rouyer M, Smith D, Laurent C, Becouarn Y, Guimbaud R, Michel P, Tubiana-Mathieu N, Balestra A, Jové J, Robinson P, Noize P, Moore N, Ravaud A, Fourrier-Réglat A; ETNA study group. Rouyer M, et al. Among authors: jove j. Target Oncol. 2016 Feb;11(1):83-92. doi: 10.1007/s11523-015-0377-6. Target Oncol. 2016. PMID: 26298481
The EULEV cohort study: rates of and factors associated with continuation of levetiracetam after 1 year.
Droz-Perroteau C, Dureau-Pournin C, Vespignani H, Marchal C, Blin P, Blazejewski S, Pollet C, Jové J, Robinson P, Moore N, Fourrier-Réglat A; EULEV Study Group. Droz-Perroteau C, et al. Among authors: jove j. Br J Clin Pharmacol. 2011 Jan;71(1):121-7. doi: 10.1111/j.1365-2125.2010.03805.x. Br J Clin Pharmacol. 2011. PMID: 21143508 Free PMC article.
Seizure freedom is not adversely affected by early discontinuation of concomitant anti-epileptic drugs in the EULEV cohort of levetiracetam users.
Droz-Perroteau C, Marchal C, Dureau-Pournin C, Lassalle R, Jové J, Robinson P, Lavernhe G, Vespignani H, Moore N, Fourrier-Réglat A; Eulev Study Group. Droz-Perroteau C, et al. Among authors: jove j. Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1183-9. doi: 10.1002/pds.3338. Epub 2012 Sep 13. Pharmacoepidemiol Drug Saf. 2012. PMID: 22972760
Real-life patterns of use and effectiveness of bortezomib: the VESUVE cohort study.
Fourrier-Réglat A, Noize P, Facon T, Fermand JP, Fitoussi O, Marit G, Thomaré P, Robinson P, Bignon E, Jové J, Lassalle R, Rouyer M, Grelaud A, Moore N; VESUVE Study Group. Fourrier-Réglat A, et al. Among authors: jove j. Leuk Lymphoma. 2014 Apr;55(4):848-54. doi: 10.3109/10428194.2013.806801. Epub 2013 Aug 28. Leuk Lymphoma. 2014. PMID: 23808815
Continuation rates of levetiracetam in children from the EULEVp cohort study.
Dureau-Pournin C, Pédespan JM, Droz-Perroteau C, Lavernhe G, Mann M, Pollet C, Robinson P, Jové J, Moore N, Fourrier-Réglat A; EULEV study group. Dureau-Pournin C, et al. Among authors: jove j. Eur J Paediatr Neurol. 2014 Jan;18(1):19-24. doi: 10.1016/j.ejpn.2013.07.003. Epub 2013 Sep 10. Eur J Paediatr Neurol. 2014. PMID: 24035600
Relative risks from case-population data.
Moore N, Gulmez SE, Blin P, Lassalle R, Jove J, Théophile H, Bégaud B, Larrey D, Bénichou J. Moore N, et al. Among authors: jove j. Epidemiology. 2013 Nov;24(6):935-6. doi: 10.1097/EDE.0b013e3182a77882. Epidemiology. 2013. PMID: 24076997 No abstract available.
Drug use in French children: a population-based study.
Bénard-Laribière A, Jové J, Lassalle R, Robinson P, Droz-Perroteau C, Noize P. Bénard-Laribière A, et al. Among authors: jove j. Arch Dis Child. 2015 Oct;100(10):960-5. doi: 10.1136/archdischild-2014-307224. Epub 2015 May 14. Arch Dis Child. 2015. PMID: 25977563
74 results